Barclays Lowers PT on Kenvue (KVUE) to $17 From $20, Keeps an Equal Weight Rating

Kenvue Inc. (NYSE:KVUE) is one of the best most oversold large cap stocks so far in 2025. On October 1, Barclays lowered the firm’s price target on Kenvue Inc. (NYSE:KVUE) to $17 from $20 while keeping an Equal Weight rating on the shares.

The firm told investors that it adjusted its models to reflect “muted and decelerating” growth in certain parts of the personal care domain since the Q2 reports.

Kenvue Inc. (NYSE:KVUE) is a consumer health company that operates through three segments: Skin Health and Beauty, Self Care, and Essential Health.

Its Skin Health and Beauty segment offers hair care, body care, face care, and other product categories. The company’s global footprint spans more than 165 countries across its four regions.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.